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Vasopressin benefits  
in-hospital cardiac arrest patients
Sudden cardiac death is common among end-stage renal dis-
ease (ESRD) patients. The resuscitation rate for these patients 
is significantly lower than among persons with normal kidney 
function; only about 30% survive their hospitalization.1,2
Mentzelopoulos et al. examined the efficacy of vasopressin 
in patients with cardiac arrest requiring epinephrine. The 
single-center, prospective, randomized, double-blind placebo-
controlled parallel-group trial included 100 subjects. They were 
randomized to receive either vasopressin (20 IU per cardio-
pulmonary resuscitation cycle) plus epinephrine (1 mg per 
resuscitation cycle; active drug arm; n = 48) or isotonic sodium 
chloride solution placebo plus epinephrine (1 mg per resusci-
tation cycle; control group; n = 52) for the first five cycles after 
randomization. The active drug arm also received 40 mg of 
methylprednisolone on the first cycle. Shock after resuscitation 
was treated with stress-dose hydrocortisone in both groups. Sub-
jects randomized to the active drug arm had a more frequent 
return of spontaneous circulation (39/48, 81%, versus 27/52, 
52%; P = 0.003) and improved survival to hospital discharge (9, 
19%, versus 2, 4%; P = 0.02). A similar benefit was seen among 
those with post-resuscitation shock. Adverse events were similar 
in both groups.
While strategies to increase survival of cardiac arrest patients 
with ESRD should be actively sought, it is not clear whether the 
conclusions from this study can be applied to the ESRD popula-
tion. Administering vasopressin to ESRD patients under cardiac 
arrest must therefore be considered carefully. However, these 
results are worth noting given the exceptionally poor survival 
of ESRD patients after cardiac arrest and the lack of research in 
this area. (Arch Intern Med 2009; 169: 15–24)
Lynda Szczech
1J Am Soc Nephrol 1992; 3: 1238–1243. 2Kidney Int 2008; 73: 933–939.
Epoxide hydrolase regulation  
of angiotensin II–induced  
cardiac hypertrophy
Among the most significant consequences of long-standing 
hypertension is cardiac hypertrophy, which is characterized 
by increased protein synthesis and cardiomyocyte size, and 
altered gene expression. Also, increased wall tension resulting 
from the hypertrophy switches the myosin heavy chain from 
the α- to the β-isoform and increases the expression of atrial 
natriuretic peptide. Many arachidonic acid metabolites have 
vascular actions and are believed to participate in the patho-
genesis of hypertension and its consequences. Arachidonic 
acid can be converted to eicosanoids via three major enzy-
matic pathways: cyclooxygenase, lipoxygenase, and CYP 450 
epoxygenase. In addition to generating hydroxylation products, 
CYP 450 epoxygenase produces four epoxyeicosatrienoic acid 
(EET) regioisomer metabolites. These compounds exert sev-
eral actions that affect cell function by increasing intracellular 
Ca2+ concentration and activating a large conductance of the 
Ca2+-activated K+ channel. EETs cause vasodilation and likely 
contribute to the action of the endothelium-derived hyperpo-
larizing factor. Soluble epoxide hydrolase (sEH; Ephx2) hydro-
lyzes the vasoactive EETs; previous studies have shown that an 
sEH inhibitor reversed the hypertensive phenotype of the spon-
taneously hypertensive rat and of rats infused with angiotensin 
II, while increasing EET levels. Thus, increased production 
of EETs by CYP 450s or decreased hydrolysis by sEH inhibi-
tion reduced blood pressure. More recent studies on pressure 
overload–induced cardiac hypertrophy also showed that sEH 
inhibition prevented cardiac enlargement, suggesting a role for 
this enzyme in the pathogenesis of both hypertension and its 
vascular consequences. Accordingly, Ai et al. recently exam-
ined the role of sEH in the pathogenesis of the cardio megaly 
in the spontaneously hypertensive rat and in rats infused with 
angiotensin II. They found that the protein level of sEH was 
elevated in the hearts of both models (Figure), and that block-
ing the angiotensin II type 1 receptor with losartan abolished 
this induction. Interestingly, administration of a potent sEH 
inhibitor prevented the pathogenesis of the angiotensin II-
induced cardiac hypertrophy, reduced cardiomyocyte size, 
and attenuated expression of hypertrophy markers, including 
atrial natriuretic peptide and β-myosin heavy chain. In neo-
natal cardiomyocytes in vitro, angiotensin II upregulated sEH 
and hypertrophy markers. The cellular responses seen in the 
wild-type cells were attenuated in cardiomyocytes from sEH−/− 
mice, suggesting that sEH not only functions as a mediator 
for the hypertrophic effect of angiotensin II but is sufficient 
for inducing cardiac hypertrophy. These results indicate that 
sEH is specifically upregulated by angiotensin II, and that it 
directly mediates the hormone-induced cardiac hypertrophy. 
The data add another level of complexity in the interaction of 
the renin–angiotensin system and arachidonic acid metabolism. 
Further, they suggest that pharmacological inhibition of sEH 
may be a useful approach to modify angiotensin II–induced 
vascular disease. (Proc Natl Acad Sci USA 2009; 106: 564–569; 
doi:10.1073/pnas.0811022106)
Juan Oliver
Plasma angiotensin II, cardiac hypertrophy, and sEH in control and 
spontaneously hypertensive rats (SHR). (a) Plasma angiotensin II (A2) 
levels. (b) Ratio of whole heart weight to body weight (HW/BW).  
(c) Sections of the rat left ventricle stained with anti-sEH antibody.
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Factors that regulate HMG CoA 
reductase during acute renal injury
Acute kidney injury evokes renal tubular cholesterol synthesis. 
However, the factors during acute kidney injury that regulate 
3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase 
(HMGCR) activity, the rate-limiting step in cholesterol synthesis, 
have not been defined. To investigate these factors, Naito et al. 
subjected mice to 30 minutes of either unilateral renal ischemia or 
sham surgery. After 3 days, bilateral nephrectomy was performed 
and cortical tissue extracts were prepared. The recruitment of RNA 
polymerase II, transcription factors (SREBP-1, SREBP-2, nuclear 
factor-κB, c-Fos, and c-Jun), and heat shock proteins (HSP-70 
and heme oxygenase-1) to the HMGCR promoter and transcrip-
tion region (start/end exons) was assessed by Matrix ChIP assay. 
HMGCR mRNA, protein, and cholesterol levels were determined. 
Finally, histone modifications at HMGCR were assessed. Ischemia/
reperfusion induced marked cholesterol loading, which corre-
sponded with elevated polymerase II recruitment to HMGCR 
and increased expression levels of both HMGCR protein and 
mRNA (Figure). Ischemia/reperfusion also induced the binding 
of the multiple transcription factors and heat shock proteins to the 
HMGCR promoter and transcription regions. Significant histone 
modifications (increased H3K4m3, H3K19Ac, and H2A.Z vari-
ants) at these loci were also observed but were not identified either 
at the 5′ and 3′ HMGCR flanking regions (±5000 bits per second) 
or at negative control genes (β-actin and β-globin). In conclusion, 
ischemia/reperfusion was found to activate the HMGCR gene via 
multiple stress-activated transcriptional and epigenetic pathways, 
contributing to renal cholesterol loading. (Am J Pathol 2009; 174: 
54–62; doi:10.2353/ajpath.2009.080602)
Marc De Broe
Evolution of kidney transplant 
recipients treated without steroids
Steroid therapy has been a central component of transplant 
immunotherapy since its early stages, but chronic steroid 
therapy is associated with numerous adverse effects. A few dec-
ades ago, much effort was directed toward developing steroid-
free immunosuppression, but enthusiasm waned after several 
studies in the 1980s showed increased risk of acute rejection 
and graft loss in the absence of steroid in low-risk kidney trans-
plant recipients. 
The more recent introduction of effective antirejection drugs, 
notably mycophenolate mofetil and thymoglobulin, reinvigor-
ated the testing of newer combinations of immunosuppressive 
agents with early withdrawal or avoidance of steroids. Initial 
studies with early steroid withdrawal yielded results comparable 
to those of steroid-containing regimens. But other studies found 
a significant increase in the incidence of early acute rejection in 
patients with no steroids. Despite these efforts, no conclusive 
data have been available to show whether the use of a steroid-
free regimen in kidney transplantation may lead to improve-
ment in patient and graft survival, mainly because studies have 
not had sufficient sample sizes or durations of follow-up. 
Hence, it remains a concern whether a steroid-free regi-
men may lead to slow deterioration of renal allograft function 
and higher allograft loss. To address this question, Luan et al. 
analyzed the outcomes of steroid-free immunosuppression 
in a population-based US group of kidney transplant recipi-
ents. All adult solitary kidney transplant recipients engrafted 
between the years 2000 and 2006 were stratified according 
to whether they were selected for a steroid-free or a steroid-
containing regimen at discharge. The study cohort consisted 
of 95,755 recipients; of these, 17.2% were discharged on ster-
oid-free maintenance immunosuppression (group 1) and the 
remaining 82.8% were discharged with a maintenance regi-
men that included a steroid preparation (group 2). The results 
showed that the adjusted graft survival at 1 and 4 years was 
96.4% and 84.6%, respectively, for group 1 (steroid-free), and 
95.4% and 82.4%, respectively, for group 2 (with steroids). The 
adjusted patient survival at 1 and 4 years was 98.3% and 92.5%, 
respectively, for group 1, and 97.7% and 90.7%, respectively, 
for group 2. Thus, the risk of graft failure in recipients on the 
steroid-free maintenance regimen (group 1) was 22% and 17% 
lower than in those with steroid at 1 and 4 years, respectively 
(P < 0.0001). Similarly, the risk of death for recipients on the 
steroid-free maintenance regimen (group 1) was 27% and 
24% lower at 1 and 4 years, respectively, compared with that 
for recipients who were discharged on the steroid-containing 
maintenance regimen (P < 0.0001). The potential benefits of 
steroid-free maintenance immunosuppression in solid-organ 
transplantation are many, including reduced incidence of 
hypertension, dyslipidemia, and hyperglycemia. The study by 
Luan et al. strongly suggests that a steroid-free regimen from 
the time of discharge following the initial transplant surgery 
is not associated with worse allograft and recipient outcomes 
and could even be beneficial, at least in some patients. It is now 
necessary to design prospective clinical studies that would iden-
tify kidney transplant recipients who are not likely to benefit 
from a steroid-free regimen. (Am J Transplant 2009; 9: 160–168; 
doi:10.1111/j.1600-6143.2008.02442.x)
Juan Oliver
Renal histological injury, as assessed at 3 days after unilateral ischemic injury.
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